Related Experiment Video
Updated: May 19, 2026

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Liver transplantation and hepatitis C
Nobuhisa Akamatsu1, Yasuhiko Sugawara
1Department of Hepato-Biliary-Pancreatic Surgery, Saitama Medical Center, Saitama Medical University, 1981 Tsujido-cho, Kamoda, Kawagoe, Saitama 350-8550, Japan.
Insights
Hepatitis C virus (HCV) reinfection after liver transplant leads to graft failure. Monitoring and timely antiviral treatment are crucial for improving outcomes in HCV-cirrhosis patients undergoing liver transplantation.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C virus (HCV)-related end-stage cirrhosis is a leading cause for liver transplantation.
- HCV reinfection post-transplant is universal, causing fibrosis, cirrhosis, and graft decompensation.
- Organ quality, especially from older donors, negatively impacts recurrence and survival.
Purpose of the Study:
- To review current understanding of HCV recurrence after liver transplantation.
- To discuss the impact of immunosuppression and organ quality on outcomes.
- To evaluate monitoring strategies and antiviral treatments for HCV recurrence.
Main Methods:
- Literature review of studies on liver transplantation for HCV cirrhosis.
- Analysis of factors influencing HCV recurrence and graft survival.
- Evaluation of current and emerging treatment strategies for post-transplant HCV.
Main Results:
- Graft reinfection with HCV is inevitable post-transplantation, leading to graft failure.
- Immunosuppression and organ quality significantly affect recurrence severity and survival.
- Pegylated interferon and ribavirin show limited efficacy (30-35% sustained viral response).
- Living-donor liver transplantation offers outcomes comparable to deceased-donor transplantation.
Conclusions:
- Close monitoring and timely antiviral therapy are essential for managing HCV recurrence.
- Optimal immunosuppressive regimens and organ selection criteria require further investigation.
- HCV cirrhosis remains a significant challenge in liver transplantation, necessitating ongoing research into effective treatments and prevention strategies.
Abstract:
Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompensation. The use of poor quality organs, particularly from older donors, has a highly negative impact on the severity of recurrence and patient/graft survival. Although immunosuppressive regimens have a considerable impact on the outcome, the optimal regimen after liver transplantation for HCV-infected patients remains unclear. Disease progression monitoring with protocol biopsy and new noninvasive methods is essential for predicting patient/graft outcome and starting antiviral treatment with the appropriate timing. Antiviral treatment with pegylated interferon and ribavirin is currently considered the most promising regimen with a sustained viral response rate of around 30% to 35%, although the survival benefit of this regimen remains to be investigated. Living-donor liver transplantation is now widely accepted as an established treatment for HCV cirrhosis and the results are equivalent to those of deceased donor liver transplantation.
Related Concept Videos
Hepatitis
Kidney Transplant I: Introduction
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cirrhosis I: Introduction
Kidney Transplant II: Surgical Procedure
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
